Pharmacogenomics in Oncology—Running Out of Excuses for Slow Adoption
JAMA Network Open · 06.12.2024 · 7 (12) · e2449453
DOI: 10.1001/jamanetworkopen.2024.49453 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 06.12.2024. Verfasst von Howard L McLeod und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Precision Medicine, Utah Tech University, St George. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
A hallmark of cancer drug therapies has been the major impact of treatment-related toxic effects, challenging the palliative and even curative goals of these interventions.Severe toxic effects can impede patients from completing their treatment courses at the target dose, potentially leading to hospitalizations and even fatalities, while also adversely affecting quality of life and increasing health
Autor:innen und Institutionen
- Center for Precision Medicine, Utah Tech University, St George.
- Department of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, Charlotte, North Carolina.
Zitieren
APA
McLeod, H. L., & Nguyen, D. G. (2024). Pharmacogenomics in Oncology—Running Out of Excuses for Slow Adoption. JAMA Network Open, 7(12), e2449453. https://doi.org/10.1001/jamanetworkopen.2024.49453
Vancouver
McLeod HL, Nguyen DG. Pharmacogenomics in Oncology—Running Out of Excuses for Slow Adoption. JAMA Network Open. 2024;7(12):e2449453. doi:10.1001/jamanetworkopen.2024.49453
BibTeX
@article{McLeod2024,
author = {McLeod, Howard L and Nguyen, D Grace},
title = {Pharmacogenomics in Oncology—Running Out of Excuses for Slow Adoption},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {12},
pages = {e2449453},
doi = {10.1001/jamanetworkopen.2024.49453}
}
EUVIMED